The National Comprehensive Cancer Network (NCCN) has published updated data on generic cancer medication shortages in the US, ...
David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how ...
Thoracotomy and intercostal minimally invasive approaches can precipitate post-thoracotomy pain syndrome via intercostal ...
Ku explains how many bispecific antibodies can act as molecular bridges, binding a tumor-associated antigen such as ...
The FDA has granted final approval to a laurylsulfate salt formulation of cabozantinib (Omcazio), converting the product’s ...
Burnout remains a significant concern among oncologists, with approximately 60% of oncologists reporting burnout, according ...
Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice ...
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed ...
The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by 3 months to March 3, 2027, for the new drug ...
Early results from the phase 2 RESTORE-PV trial suggest that the investigational monoclonal antibody DISC-3405 has the ...
Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.
Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results